Bronchial carcinoma. III. Quantitative measurements of the quality of survival. A prospective randomized study of the result of therapy in inoperable patients with localized disease.
Fifty-four bronchial carcinoma patients in clinico-anatomical stages 1-3 of the disease (localized disease) were randomly assigned to groups for radiotherapy, cyclophosphamide and placebo treatment, respectively. The results were assessed by the survival time and the quality of survival. The median survival time was 6.7 months for radiotherapy, 12.4 months for cyclophosphamide and 11.3 months for placebo. The median total sum of vitagram points was 44.5 for radiotherapy, 90.2 for cyclophosphamide and 81.8 for placebo. When calculated per month, the median sum of vitagram points was 6.2 for radiotherapy, 6.6 for cyclophosphamide and 7.0 for placebo. No significant differences were found between the treatment groups with respect to average survival time and and average vitagram point sums.
D000328:Adult; D000368:Aged; D001984:Bronchial Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000503:physiopathology / Q000532:radiotherapy / Q000628:therapy; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011379:Prognosis; D011446:Prospective Studies; D011788:Quality of Life; D013223:Statistics as Topic; D013548:Sweden; D013997:Time Factors
D010919:Placebos; D003520:Cyclophosphamide